Wealth Enhancement Advisory Services LLC Raises Stock Position in Cencora, Inc. $COR

Wealth Enhancement Advisory Services LLC increased its position in Cencora, Inc. (NYSE:COR) by 0.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 279,905 shares of the company’s stock after purchasing an additional 2,135 shares during the period. Wealth Enhancement Advisory Services LLC owned 0.14% of Cencora worth $86,409,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC lifted its holdings in Cencora by 69.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the period. Caldwell Trust Co bought a new stake in Cencora during the second quarter valued at approximately $46,000. Salomon & Ludwin LLC increased its stake in shares of Cencora by 638.1% in the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after purchasing an additional 134 shares in the last quarter. Finally, Capital A Wealth Management LLC raised its stake in shares of Cencora by 3,975.0% in the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after buying an additional 159 shares during the period. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the transaction, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 15,220 shares of company stock valued at $5,343,561. 10.80% of the stock is owned by company insiders.

Cencora Stock Performance

Cencora stock traded up $1.44 during midday trading on Tuesday, hitting $356.29. 60,926 shares of the company were exchanged, compared to its average volume of 1,027,714. The business has a fifty day simple moving average of $349.45 and a two-hundred day simple moving average of $320.73. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The firm has a market capitalization of $69.12 billion, a PE ratio of 44.77, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. Cencora, Inc. has a fifty-two week low of $237.71 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the prior year, the firm posted $3.34 EPS. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on COR shares. Mizuho upped their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. boosted their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Bank of America lowered their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Barclays initiated coverage on shares of Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $381.42.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.